Concomitant diabetes mellitus and heart failure.

[1]  J. O’Keefe,et al.  Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers for Prevention of Type 2 Diabetes , 2016 .

[2]  M. Krause,et al.  Blockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects , 2014, Diabetes.

[3]  M. Monami,et al.  Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[4]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[5]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[6]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[7]  J. Spertus,et al.  Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina). , 2013, Journal of the American College of Cardiology.

[8]  S. Solomon,et al.  Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. , 2013, JAMA.

[9]  M. Metra,et al.  Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. , 2013, Endocrine, metabolic & immune disorders drug targets.

[10]  M. Gheorghiade,et al.  Mitochondria as a therapeutic target in heart failure. , 2013, Journal of the American College of Cardiology.

[11]  Mark D. Huffman,et al.  Association between diabetes mellitus and post‐discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial , 2013, European journal of heart failure.

[12]  G. Remuzzi,et al.  Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. , 2013, Translational research : the journal of laboratory and clinical medicine.

[13]  Xiaoshu Cheng,et al.  Levels of B-type natriuretic peptide in chronic heart failure patients with and without diabetes mellitus , 2012, Experimental and therapeutic medicine.

[14]  N. Dhalla,et al.  Role of microangiopathy in diabetic cardiomyopathy , 2013, Heart Failure Reviews.

[15]  M. Rutter,et al.  Incretins as a novel therapeutic strategy in patients with diabetes and heart failure , 2013, Heart Failure Reviews.

[16]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[17]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[18]  Akshay S. Desai,et al.  Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). , 2012, Journal of the American College of Cardiology.

[19]  Arshed A Quyyumi,et al.  Endothelial dysfunction, arterial stiffness, and heart failure. , 2012, Journal of the American College of Cardiology.

[20]  C. Reichetzeder,et al.  Renal and Cardiac Effects of DPP4 Inhibitors – from Preclinical Development to Clinical Research , 2012, Kidney and Blood Pressure Research.

[21]  J. McMurray,et al.  Eplerenone and new‐onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS‐HF) , 2012, European journal of heart failure.

[22]  Salim Yusuf,et al.  Basal insulin and cardiovascular and other outcomes in dysglycemia. , 2012, The New England journal of medicine.

[23]  M. Böhm,et al.  Hypo- and hyperglycemia predict outcome in patients with left ventricular dysfunction after acute myocardial infarction: data from EPHESUS. , 2012, Journal of cardiac failure.

[24]  A. Mebazaa,et al.  Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. , 2012, International journal of cardiology.

[25]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[26]  M. Metra,et al.  Six‐year prognosis of diabetic patients with coronary artery disease , 2012, European journal of clinical investigation.

[27]  J. Ge,et al.  Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. , 2012, Journal of the American College of Cardiology.

[28]  L. Maier,et al.  Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. , 2012, Pharmacology & therapeutics.

[29]  L. Cai,et al.  Endoplasmic Reticulum Stress and Diabetic Cardiomyopathy , 2011, Experimental diabetes research.

[30]  K. Swedberg,et al.  Effect of Enalapril on Mortality in Congestive Heart Failure , 2012, Drugs.

[31]  A. Vaag,et al.  Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. , 2011, Diabetes research and clinical practice.

[32]  B. Hoogwerf,et al.  CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular safety of exenatide BID: an , 2022 .

[33]  P. Hruz,et al.  Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy , 2011, PloS one.

[34]  C. Jellis,et al.  Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus. , 2011, The American journal of cardiology.

[35]  G. Parati,et al.  Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure , 2011, Journal of cardiovascular medicine.

[36]  C. Anderson,et al.  Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure , 2010, Cardiovascular diabetology.

[37]  R. Parakhia,et al.  Metformin Activates AMP Kinase through Inhibition of AMP Deaminase , 2010, The Journal of Biological Chemistry.

[38]  M. J. Hall,et al.  National Hospital Discharge Survey: 2007 summary. , 2010, National health statistics reports.

[39]  B. Hoogwerf,et al.  Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies , 2010, Diabetes Care.

[40]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[41]  Sumit R. Majumdar,et al.  Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database , 2010, Diabetes Care.

[42]  E. Braunwald,et al.  Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary Syndrome , 2010, Diabetes Care.

[43]  J. Fleg,et al.  Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial , 2010, Diabetes Care.

[44]  G. Fonarow,et al.  Metformin therapy and outcomes in patients with advanced systolic heart failure and diabetes. , 2010, Journal of cardiac failure.

[45]  F. Villarreal,et al.  Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis. , 2010, Journal of molecular and cellular cardiology.

[46]  S. Matsuo,et al.  eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. , 2010, The American journal of pathology.

[47]  P. Elliott,et al.  Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database , 2009, BMJ : British Medical Journal.

[48]  P. Neufer,et al.  Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. , 2009, Journal of the American College of Cardiology.

[49]  H. Krum,et al.  Inhibition of Protein Kinase C–β by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy , 2009, Circulation. Heart failure.

[50]  Richard Donnelly,et al.  Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drug , 2009, Diabetes, obesity & metabolism.

[51]  C. Nichols,et al.  Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. , 2009, Trends in cardiovascular medicine.

[52]  R. Henkelman,et al.  GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice , 2009, Diabetes.

[53]  D. Tepper,et al.  Pioglitazone and Heart Failure: Results From a Controlled Study in Patients With Type 2 Diabetes Mellitus and Systolic Dysfunction , 2008 .

[54]  I. Poornima,et al.  Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat , 2008, Circulation. Heart failure.

[55]  F. McAlister,et al.  The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy , 2008, European journal of heart failure.

[56]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[57]  Karl Swedberg,et al.  Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. , 2008, European heart journal.

[58]  S. Twigg,et al.  Fibrosis in diabetes complications: Pathogenic mechanisms and circulating and urinary markers , 2008, Vascular health and risk management.

[59]  D. Drucker,et al.  Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways , 2008, Circulation.

[60]  大谷 朋仁.  Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure : beneficial effects of mineralocorticoid receptor blocker , 2008 .

[61]  D. J. Veldhuisen,et al.  Advanced glycation end‐products (AGEs) and heart failure: Pathophysiology and clinical implications , 2007, European journal of heart failure.

[62]  K. Seung,et al.  Serum carboxy-terminal propeptide of type I procollagen (PIP) is a marker of diastolic dysfunction in patients with early type 2 diabetes mellitus. , 2007, International journal of cardiology.

[63]  K. Dickstein,et al.  How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. , 2007, European heart journal.

[64]  A. Lincoff,et al.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. , 2007, JAMA.

[65]  F. McAlister,et al.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.

[66]  P. Ponikowski,et al.  A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. , 2007, Clinical science.

[67]  G. Fonarow,et al.  Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). , 2007, American heart journal.

[68]  P. Poole‐Wilson,et al.  Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) , 2007, Heart.

[69]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[70]  H. Tsutsui.  [Candesartan in heart failure: assessment of reduction in mortality and morbidity]. , 2007, Nihon rinsho. Japanese journal of clinical medicine.

[71]  J. Seidman,et al.  AMP-Activated Protein Kinase in the Heart: Role During Health and Disease , 2007, Circulation research.

[72]  B. Kemp,et al.  AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling , 2007, Circulation research.

[73]  R. Shannon,et al.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. , 2006, Journal of cardiac failure.

[74]  N. Dhalla,et al.  Blockade of the Renin–Angiotensin System Attenuates Sarcolemma and Sarcoplasmic Reticulum Remodeling in Chronic Diabetes , 2006, Annals of the New York Academy of Sciences.

[75]  P. Ponikowski,et al.  EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. , 2006, European heart journal.

[76]  O. Alfieri,et al.  A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. , 2006, Journal of the American College of Cardiology.

[77]  E. Abel,et al.  Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. , 2006, Physiology.

[78]  V. Roger,et al.  Diabetes in heart failure: prevalence and impact on outcome in the population. , 2006, The American journal of medicine.

[79]  G. Lopaschuk,et al.  AMPK alterations in cardiac physiology and pathology: enemy or ally? , 2006, The Journal of physiology.

[80]  P. Ghezzi,et al.  Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. , 2006, Life sciences.

[81]  Ting Zhao,et al.  Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts , 2006, Journal of Pharmacology and Experimental Therapeutics.

[82]  H. Yoshimatsu,et al.  Brain natriuretic peptide and cardiac autonomic function in type 2 diabetic patients. , 2006, Diabetes research and clinical practice.

[83]  C. Szabó,et al.  Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. , 2006, Current opinion in pharmacology.

[84]  J. McGill,et al.  Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. , 2006, Journal of the American College of Cardiology.

[85]  J. Leahy.  Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure , 2006 .

[86]  G. Fonarow,et al.  An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. , 2006, American heart journal.

[87]  P. Schrauwen,et al.  Putative function and physiological relevance of the mitochondrial uncoupling protein-3: involvement in fatty acid metabolism? , 2006, Progress in lipid research.

[88]  P. Kowey,et al.  Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. , 2005, The American journal of cardiology.

[89]  R. Cooksey,et al.  Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. , 2005, Endocrinology.

[90]  K. Clarke,et al.  Metabolic Modulation With Perhexiline in Chronic Heart Failure: A Randomized, Controlled Trial of Short-Term Use of a Novel Treatment , 2005, Circulation.

[91]  E. Abel,et al.  Reduced Mitochondrial Oxidative Capacity and Increased Mitochondrial Uncoupling Impair Myocardial Energetics in Obesity , 2005, Circulation.

[92]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[93]  Ross T Tsuyuki,et al.  Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. , 2005, Diabetes care.

[94]  J. O’Keefe,et al.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. , 2005, Journal of the American College of Cardiology.

[95]  R. Gibbons,et al.  Improved Survival in Asymptomatic Diabetic Patients With High-Risk Spect Imaging Treated With Coronary Artery Bypass Grafting , 2005, Circulation.

[96]  S. Kihara,et al.  Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. , 2005, American journal of hypertension.

[97]  G. King,et al.  Differential Regulation of Angiotensin II-induced Expression of Connective Tissue Growth Factor by Protein Kinase C Isoforms in the Myocardium* , 2005, Journal of Biological Chemistry.

[98]  Vilmundur Gudnason,et al.  The association between glucose abnormalities and heart failure in the population-based Reykjavik study. , 2005, Diabetes care.

[99]  H. Krumholz,et al.  Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study , 2005, Circulation.

[100]  T. Marwick,et al.  Screening for heart disease in diabetic subjects. , 2005, American heart journal.

[101]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[102]  P. Howard,et al.  Eplerenone: A Selective Aldosterone Receptor Antagonist for Patients with Heart Failure , 2005, The Annals of pharmacotherapy.

[103]  P. Deedwania,et al.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. , 2005, American heart journal.

[104]  G. Fonarow,et al.  Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. , 2005, American heart journal.

[105]  Alistair A Young,et al.  Three-dimensional assessment of left ventricular systolic strain in patients with type 2 diabetes mellitus, diastolic dysfunction, and normal ejection fraction. , 2004, The American journal of cardiology.

[106]  L. Rydén,et al.  Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes , 2004, Heart.

[107]  G. Lamas,et al.  Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. , 2004, Archives of internal medicine.

[108]  G. Noon,et al.  Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  W. Pierce,et al.  Cardiac mitochondrial damage and biogenesis in a chronic model of type 1 diabetes. , 2004, American journal of physiology. Endocrinology and metabolism.

[110]  S. Solomon,et al.  Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction: Results of the CHARM Low–Left Ventricular Ejection Fraction Trials , 2004, Circulation.

[111]  S. Mudaliar,et al.  Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. , 2004, Journal of the American College of Cardiology.

[112]  A. Laupacis,et al.  Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study , 2004 .

[113]  C. Gullion,et al.  The incidence of congestive heart failure in type 2 diabetes: an update. , 2004, Diabetes care.

[114]  Thomas H Marwick,et al.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. , 2004, Endocrine reviews.

[115]  Graves Ej,et al.  National Hospital Discharge Survey , 2004 .

[116]  C. Dence,et al.  Effect of Obesity and Insulin Resistance on Myocardial Substrate Metabolism and Efficiency in Young Women , 2004, Circulation.

[117]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[118]  N. Lamblin,et al.  Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. , 2004, European heart journal.

[119]  Julio E. Pérez,et al.  Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. , 2004, The American journal of cardiology.

[120]  J. Piccini,et al.  New insights into diastolic heart failure: role of diabetes mellitus. , 2004, The American journal of medicine.

[121]  R. Bonow,et al.  The diabetes epidemic: a national and global crisis. , 2004, The American journal of medicine.

[122]  C. Torp‐Pedersen,et al.  Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. , 2004, Journal of the American College of Cardiology.

[123]  W. Hundley,et al.  Heart failure prevalence, incidence, and mortality in the elderly with diabetes. , 2004, Diabetes care.

[124]  K. Malmberg,et al.  Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. , 2004, Journal of the American College of Cardiology.

[125]  M. Noble,et al.  Chronic Catecholamine Depletion Switches Myocardium from Carbohydrate to Lipid Utilisation , 2001, Cardiovascular Drugs and Therapy.

[126]  N. Dhalla,et al.  Modification of myosin isozymes and SR Ca2+-pump ATPase of the diabetic rat heart by lipid-lowering interventions , 1994, Molecular and Cellular Biochemistry.

[127]  M. Metra,et al.  Efficacy and tolerability of the long‐term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus , 2003, European journal of heart failure.

[128]  Albert W Wu,et al.  Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. , 2003, Journal of the American College of Cardiology.

[129]  M. Domanski,et al.  The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. , 2003, Journal of the American College of Cardiology.

[130]  Markku Peltonen,et al.  Impact of blood pressure and insulin on the relationship between body fat and left ventricular structure. , 2003, European heart journal.

[131]  L. Tavazzi,et al.  Survival and hospitalization in heart failure patients with or without diabetes treated with beta-blockers. , 2003, Journal of cardiac failure.

[132]  Paul G Shekelle,et al.  Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. , 2003, Journal of the American College of Cardiology.

[133]  B. Pitt,et al.  Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .

[134]  M. Pfeffer,et al.  Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.

[135]  N. Freemantle,et al.  The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment , 2003 .

[136]  N Freemantle,et al.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. , 2003, European heart journal.

[137]  B. Pitt,et al.  EPLERENONE POST-ACUTE MYOCARDIAL INFARCTION HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS. EPLERENONE, A SELECTIVE ALDOSTERONE BLOCKER, IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION AFTER MYOCARDIAL INFARCTION , 2003 .

[138]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[139]  G. King,et al.  Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. , 2002, Diabetes.

[140]  M. Gheorghiade,et al.  &bgr;-Blockers in the Post-Myocardial Infarction Patient , 2002, Circulation.

[141]  S. Rajagopalan,et al.  Mineralocorticoid Receptor Antagonism in Experimental Atherosclerosis , 2002, Circulation.

[142]  D. Belke,et al.  Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. , 2002, Diabetes.

[143]  É. Szabó,et al.  The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. , 2002, Diabetes.

[144]  M. Schocke,et al.  Decreased high-energy phosphate ratios in the myocardium of men with diabetes mellitus type I. , 2002, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[145]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[146]  P. Cryer.  Hypoglycemia-associated autonomic failure in diabetes. , 2001, American journal of physiology. Endocrinology and metabolism.

[147]  D. Ziegler.  Diagnosis and treatment of diabetic autonomic neuropathy , 2001, Current diabetes reports.

[148]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[149]  A. Struthers.  Review: Aldosterone-induced vasculopathy: a new reversible cause of cardiac death , 2001, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[150]  R. Lancashire,et al.  Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.

[151]  W. Hermann,et al.  Results from post‐hoc analyses of the CIBIS II trial: effect of bisoprolol in high‐risk patient groups with chronic heart failure , 2001 .

[152]  Jennifer Y. Liu,et al.  Glycemic Control and Heart Failure Among Adult Patients With Diabetes , 2001, Circulation.

[153]  B V Howard,et al.  The impact of diabetes on left ventricular filling pattern in normotensive and hypertensive adults: the Strong Heart Study. , 2001, Journal of the American College of Cardiology.

[154]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[155]  H. Brunner.  Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. , 2001, The American journal of cardiology.

[156]  F. Maklady,et al.  Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. , 2001, The American journal of cardiology.

[157]  P. Poole‐Wilson,et al.  Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. , 2000, European heart journal.

[158]  V. Fuster,et al.  Coronary Composition and Macrophage Infiltration in Atherectomy Specimens From Patients With Diabetes Mellitus , 2000, Circulation.

[159]  G. Lopaschuk,et al.  The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. , 2000, Circulation research.

[160]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[161]  G. Reaven,et al.  Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited. , 1999, Metabolism: clinical and experimental.

[162]  L. Køber,et al.  Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. , 1999, Journal of the American College of Cardiology.

[163]  S. Jacob,et al.  Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? , 1998, American journal of hypertension.

[164]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[165]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[166]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[167]  R. Ziegler,et al.  AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.

[168]  D. Brindley,et al.  Effects of Cell-Permeable Ceramides and Tumor Necrosis Factor-α on Insulin Signaling and Glucose Uptake in 3T3-L1 Adipocytes , 1998, Diabetes.

[169]  W. Motz,et al.  Impaired Coronary Flow Reserve in NIDDM: A Possible Role for Diabetic Cardiopathy in Humans , 1997, Diabetes.

[170]  P. Fiorina,et al.  Isolated and preclinical impairment of left ventricular filling in insulin‐dependent and non‐insulin‐dependent diabetic patients , 1997, Clinical cardiology.

[171]  G. Paolisso,et al.  Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. The Osservatorio Geriatrico Regione Campania Group. , 1997, Diabetes & metabolism.

[172]  A. Malhotra,et al.  Regulation of contractile proteins in diabetic heart. , 1997, Cardiovascular research.

[173]  B. Magnani,et al.  Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. , 1996, The American journal of cardiology.

[174]  S. Yusuf,et al.  Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. , 1996, The American journal of cardiology.

[175]  J. Levy,et al.  U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease , 1995, Diabetes.

[176]  C. White,et al.  Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. , 1995, Circulation.

[177]  D. Raev.  Which Left Ventricular Function Is Impaired Earlier in the Evolution of Diabetic Cardiomyopathy?: An echocardiographic study of young type I diabetic patients , 1994, Diabetes Care.

[178]  B. Davis,et al.  Uniformity of captopril benefit in the SAVE study : subgroup analysis , 1994 .

[179]  W. Rathmann,et al.  Mortality in Diabetic Patients with Cardiovascular Autonomic Neuropathy , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[180]  S. Yusuf,et al.  Natural history and patterns of current practice in heart failure , 1993 .

[181]  J. Neaton,et al.  Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.

[182]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[183]  M. Lishner,et al.  Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic nervous control in chronic renal failure. , 1987, Nephron.

[184]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.